NATICK, Mass., April 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX - News) today announced that the Company has resolved the deficiencies in the warning letter issued by the U.S. Food and Drug Administration (FDA) to the Guidant Corporation on December 22, 2005, and that all associated restrictions have been removed. Boston Scientific acquired Guidant last year.
